<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026857</url>
  </required_header>
  <id_info>
    <org_study_id>ST261 DM 01 004</org_study_id>
    <nct_id>NCT01026857</nct_id>
  </id_info>
  <brief_title>Propionyl-L-Carnitine in Ulcerative Colitis</brief_title>
  <official_title>Phase II, Parallel-group, Placebo Controlled, Double-blind, Randomised, Multicenter Study to Investigate the Efficacy of Two Dosages of Propionyl-L-Carnitine Colon Release Tablets in Patients Affected by Ulcerative Colitis Under Oral Stable Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>sigma-tau i.f.r. S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>sigma-tau i.f.r. S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Propionyl-L-carnitine administration may
      ameliorate the illness in patients affected by mild to moderate ulcerative colitis already in
      treatment with one of the standard treatments (corticosteroids excluded).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial foresees the administration of 2 different dosages of Propionyl-L-carnitine (ST261)
      colon release tablets, 1 g/die and 2 g/die. The primary objective of this trial is to
      evaluate the clinical/endoscopic response defined as a lowering of the Disease Activity Index
      (DAI score) of at least 3 points ot the reaching of remission, the clinical/endoscopic
      remission (DAI score &lt;= 2 with no individual subscore &gt; 1) and histological efficacy of the
      two combined dosages of PLC (i.e. PLC 1 g/die + 2 g/die) in comparison to placebo, defined as
      an improvement of the Histological Index (HI) of at least 1 point at the end of the study (a
      final HI score of &lt;= 1 will be defined as an histological remission).

      The secondary objective is to evaluate the clinical/endoscopic and histological efficacy of
      the two dosages of PLC individually considered in comparison to Placebo, in order to gather
      information on the dosage to be used in subsequent trials. The safety and tolerability of the
      regimens studied will also be objectives of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Activity Index score</measure>
    <time_frame>baseline, week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>PLC Colon release tablet 1 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 patients each arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLC colon release tablet 2 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 patients each arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo PLC colon release tablet 2 g</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>40 patients each arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propionyl-L-Carnitine</intervention_name>
    <description>PLC colon release tablet 1 g/die for 4 weeks</description>
    <arm_group_label>PLC Colon release tablet 1 g</arm_group_label>
    <other_name>Dromos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propionyl-L-Carnitine</intervention_name>
    <description>PLC colon release tablet 2 g/die for 4 weeks</description>
    <arm_group_label>PLC colon release tablet 2 g</arm_group_label>
    <other_name>Dromos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo PLC colon release tablet 2 g/die for 4 weeks</description>
    <arm_group_label>PLC Colon release tablet 1 g</arm_group_label>
    <arm_group_label>PLC colon release tablet 2 g</arm_group_label>
    <arm_group_label>Placebo PLC colon release tablet 2 g</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have read the Information for the Patient and signed the Informed Consent Form.

          -  Age comprised between 18 and 75 included.

          -  If female, not pregnant or nursing.

          -  For women of childbearing potential, willingness to avoid a pregnancy during the
             treatment period and for at least 1 month from the last dose of drug.

          -  Availability of a pancolonoscopy and histology both confirming the diagnosis of active
             ulcerative colitis.

          -  Disease Activity Index comprised between 3 and 10, inclusive, (mild to moderate
             ulcerative colitis).

          -  On one of the following treatments for ulcerative colitis prior to baseline visit:

               1. Stable background oral aminosalicylates (mesalazine, balsalazide, olsalazine) or
                  sulfasalazine therapy for greater than or equal to 4 weeks prior to baseline
                  assessments.

               2. Stable background mercaptopurine or azathioprine for greater than or equal to 12
                  weeks prior to baseline assessments.

        Exclusion Criteria:

          -  First diagnosis of ulcerative colitis.

          -  Crohn's disease.

          -  Current or previous (in the last 10 days preceding the screening) use of systemic
             corticosteroids.

          -  Use of antibiotics in the last 10 days preceding the screening.

          -  Use of NSAID's in the last 10 days preceding the screening.

          -  Use of probiotics in the last 10 days preceding the screening

          -  Positive stool culture (when performed, according to Investigator's judgment, to
             assess possible parasitologic infection(s)).

          -  Significantly impaired liver, renal, pulmonary or cardiovascular function.

          -  History of colon resection.

          -  Diverticulitis.

          -  Diagnosis of proctitis

          -  Stable rectally administered therapy in the last 10 days.

          -  Active or chronic infection(s).

          -  Simultaneous participation in another clinical trial, or participation in any clinical
             trial involving investigational drugs within 3 months from enrolment into the present
             study.

          -  Any physical or psychological condition in a patient that could let the investigator
             suspect his/her poor compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni B. Gasbarrini, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico Universitario &quot;A. Gemelli&quot; - Rome - Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabriele Bianchi Porro, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale &quot;L. Sacco&quot; - Milan - Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Agesilao D'Arienzo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. Universitaria Federico II - Naples - Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniela Valpiani, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>P.O. Morgagni Pierantoni - Forlì - Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maurizio Koch, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale &quot;S. Filippo Neri&quot; - Rome - Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ewa Malecka-Panas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinika Przewodu Pokarmowego Szpital Kliniczny Nr 1 - Lodz - Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leszek Paradowski, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samodzielny Publiczny Szpital Kliniczny Nr 3 - Wroclaw - Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Konrad Lesniakowski, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wojewodzki Szpital - Wroclaw - Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Limas Kupcinskas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaunas Medical University Clinic - Kaunas - Lithuania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Goda Denapiene, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vilnius University Santariskiu Hospital - Vilnius - Lithuania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vladimir B. Grinevich, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Institution &quot;Regional Military Clinical Hospital N°422 named after Solovyov of Ministry of Defence of Russia - Saint Petersburg - Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elena Sishkova, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Healthcare Institution &quot;Clinical Hospital N°122 named after L.G. Sokolov of Federal Medical and Biological Agency&quot; - Saint Petersburg - Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Konstantin P. Zhidkov, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Petersburg State Healthcare Institution &quot;Municipal Hospital N°26&quot; - Saint Petersburg - Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Igor G. Bakulin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Institution &quot;7th Central Military Clinical Aviation Hospital of Ministry of Defence of Russia&quot; - Moscow - Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tatiana L. Mikhailova, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Institution &quot;State Scientific Centre of Coloproctology of Rosmedtechnologij&quot; - Moscow - Russia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Morgagni - Pierantoni</name>
      <address>
        <city>Forlì</city>
        <zip>47100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;L. Sacco&quot;</name>
      <address>
        <city>Milan</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Federico II</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital S. Filippo Neri</name>
      <address>
        <city>Rome</city>
        <zip>00135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico &quot;A. Gemelli&quot;</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaunas Medical University Clinic</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius University Santariskiu Hospital</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Przewodu Pokarmowego Szpital Kliniczny Nr 1</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 3 Katedra i Klinika Gastroenterologii AM</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-326</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny Klinika Gastroenterologii</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-149</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution &quot;7-th Central Military Clinical Aviation Hospital of Ministry of Defence of Russia&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>107014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution &quot;State Scientific Centre of Coloproctology of Rosmedtechnologij&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>123154</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution &quot;Regional Military Clinical Hospital № 442 named after Z.P. Solovyov of Ministry of Defence of Russia&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>193163</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Healthcare Institution &quot;Clinical Hospital № 122 named after L.G. Sokolov of Federal Medical and Biological Agency&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St-Petersburg State Healthcare Institution &quot;Municipal Hospital № 26&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2009</study_first_submitted>
  <study_first_submitted_qc>December 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2009</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

